Concurrent Chemoradiotherapy with S-1 as First-line Treatment for Patients with Oropharyngeal Cancer

被引:16
作者
Ohnishi, Kayoko [1 ]
Shioyama, Yoshiyuki [1 ]
Nakamura, Katsumasa [2 ]
Nakashima, Torahiko [3 ]
Ohga, Saiji [1 ]
Nonoshita, Takeshi [1 ]
Yoshitake, Tadamasa [1 ]
Terashima, Kotarou [1 ]
Komune, Shizuo [3 ]
Honda, Hiroshi [1 ]
机构
[1] Kyushu Univ, Dept Clin Radiol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ Hosp, Dept Radiol, Beppu, Oita 8740838, Japan
[3] Kyushu Univ, Dept Otorhinolaryngol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
Concurrent chemoradiotherapy; S-1; Oropharyngeal cancer; SQUAMOUS-CELL CARCINOMA; FLUOROPYRIMIDINE ANTICANCER AGENT; RADIATION-THERAPY; ORAL FLUOROPYRIMIDINE; CONCOMITANT CHEMOTHERAPY; GLOTTIC CARCINOMA; LOCAL-CONTROL; NECK-CANCER; RADIOTHERAPY; HEAD;
D O I
10.1269/jrr.10081
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: S-1 is an oral fluoropyrimidine. The purpose of this study was to review the clinical outcomes of S-1 with concurrent radiotherapy for patients with oropharyngeal cancer. Materials and Methods: Between 2002 and 2007, 38 patients with oropharyngeal cancer treated concurrently with S-1 and definitive radiotherapy were reviewed. The clinical stage was Stage I in 4 patients, Stage II in 7, Stage III in 7, and Stage IV in 20. S-1 was administered orally twice daily for 4 consecutive weeks followed by a 2-week drug withdrawal. The initial dose of S-1 was 65 mg/m(2)/day. All patients were treated using three-dimensional conformal radiotherapy with a median total dose of 65.1 Gy (range, 60.0-71.0 Gy). Clinical outcomes and major acute toxicities were analyzed based on medical records and clinical follow-up. Results: With a median follow-up time of 33 months, the 3-year estimates of local-regional control, distant metastases-free survival, disease-free survival, and overall survival for all patients were 75%, 80%, 65%, and 80%, respectively. The 3-year estimates of local-regional control according to stage were 100% for Stages I and II, 86% for Stage III, and 56% for Stage IV. The rate of Grade 3 acute mucositis was 32%, and the rate of >= Grade 3 hematological toxicities was 8%. No other severe toxicities were observed. Conclusions: Concurrent chemoradiotherapy with S-1 was found to be effective, especially for early disease. The treatment-related toxicities were acceptable, and the incidence of myelotoxicity was low. Further study must be carried out to compare with other chemotherapy regimens.
引用
收藏
页码:47 / 53
页数:7
相关论文
共 50 条
[41]   Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy [J].
Liu, Jing ;
Tang, Guyu ;
Zhou, Qin ;
Kuang, Weilu .
RADIATION ONCOLOGY, 2022, 17 (01)
[42]   Prospective study of definitive chemoradiotherapy with S-1 and nedaplatin in patients with stage II/III (non-T4) esophageal cancer [J].
Tsuda, Takashi ;
Inaba, Hiroyuki ;
Miyazaki, Aya ;
Izawa, Naoki ;
Hirakawa, Mami ;
Watanabe, Yoshiyuki ;
Kitajima, Satoshi ;
Hoshikawa, Yoshikazu ;
Gomi, Hiromichi ;
Kimura, Masayuki ;
Itoh, Fumio .
ESOPHAGUS, 2011, 8 (01) :45-51
[43]   Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis [J].
Kitani, Yosuke ;
Kubota, Akira ;
Furukawa, Madoka ;
Hori, Yukiko ;
Nakayama, Yuko ;
Nonaka, Tetsuo ;
Mizoguchi, Nobutaka ;
Kitani, Yuka ;
Hatakeyama, Hiromitsu ;
Oridate, Nobuhiko .
ORAL ONCOLOGY, 2017, 71 :54-59
[44]   Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results [J].
Feng, Felix Y. ;
Kim, Hyungjin M. ;
Lyden, Teresa H. ;
Haxer, Marc J. ;
Worden, Francis P. ;
Feng, Mary ;
Moyer, Jeffrey S. ;
Prince, Mark E. ;
Carey, Thomas E. ;
Wolf, Gregory T. ;
Bradford, Carol R. ;
Chepeha, Douglas B. ;
Eisbruch, Avraham .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2732-2738
[45]   Intraarterial chemotherapy as the first-line therapy in penile cancer [J].
Chiang, P-H ;
Chen, C-H ;
Shen, Y-C .
BRITISH JOURNAL OF CANCER, 2014, 111 (06) :1089-1094
[46]   Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience [J].
Lorch, Jochen H. ;
Hanna, Glenn J. ;
Posner, Marshall R. ;
O'Neill, Anne ;
Thotakura, Vijaya L. ;
Limaye, Sewanti A. ;
Rabinowits, Guilherme ;
Sher, David J. ;
Tishler, Roy B. ;
Haddad, Robert I. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 :E1618-E1624
[47]   Concurrent Chemoradiotherapy in the Treatment of Locally Recurrent Rectal Cancer [J].
You, Yau-Tong ;
Chen, Jinn-Shiun ;
Wang, Jeng-Yi ;
Tang, Reiping ;
Changchien, Chung-Rong ;
Chiang, Jy-Ming ;
Yeh, Chien-Yuh ;
Hsieh, Pao-Shiu ;
Tasi, Wen-Sy ;
Hung, Hsin-Yuan ;
You, Jeng-Fu ;
Chiang, Sum-Fu .
HEPATO-GASTROENTEROLOGY, 2013, 60 (121) :94-98
[48]   Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy [J].
Lim, Sung Hee ;
Lee, Su Jin ;
Ahn, Myung-Ju ;
Park, Keunchil ;
Sun, Jong-Mu .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (01) :40-45
[49]   Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy [J].
Dietrich, Nicholas ;
Watson, Erin ;
Tadic, Tony ;
Martino, Rosemary ;
Bratman, Scott ;
Cho, John ;
de Almeida, John ;
Eng, Lawson ;
Goldstein, David ;
Hahn, Ezra ;
Hope, Andrew ;
Hosni, Ali ;
Kim, John ;
Malik, Nauman ;
O'Sullivan, Brian ;
Garcia, Enrique Sanz ;
Siu, Lillian ;
Spreafico, Anna ;
Su, Susie ;
Tsai, Jillian ;
Waldron, John ;
Yao, Christopher M. K. L. ;
Huang, Shao Hui ;
Mcpartlin, Andrew J. .
ORAL ONCOLOGY, 2025, 161
[50]   Zoledronic Acid in First-Line Treatment of Prostate Cancer [J].
Pinkawa, Michael .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 97 (01) :6-8